Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study

Abstract Standard treatment for severe Clostridium difficile infection (CDI) is oral vancomycin with metronidazole. After failure of this standard regimen, treatment becomes challenging. A young woman treated for septic shock developed CDI. Standard treatment failed and she was ineligible for fecal transplant. Addition of tigecycline to her regimen resulted in cure.

Download Full-text

PCR based detection of tcdCΔ117 in Clostridium difficile infection identifies patients at risk for recurrence – A hospital-based prospective observational study

Anaerobe ◽

10.1016/j.anaerobe.2019.03.010 ◽

2019 ◽

Vol 57 ◽

pp. 39-44 ◽

Cited By ~ 1

Author(s):

N. Jazmati ◽

O. Hain ◽

M. Hellmich ◽

G. Plum ◽

A. Kaasch

Keyword(s):

At Risk ◽

Clostridium Difficile ◽

Observational Study ◽

Clostridium Difficile Infection ◽

Prospective Observational Study ◽

Patients At Risk

Download Full-text

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection

Open Forum Infectious Diseases ◽

10.1093/ofid/ofx163.969 ◽

2017 ◽

Vol 4 (suppl_1) ◽

pp. S390-S390

Author(s):

Sunish Shah ◽

Benjamin Ereshefsky ◽

Laura Pontiggia ◽

Michael Cawley

Keyword(s):

Clostridium Difficile ◽

Hospital Mortality ◽

Clostridium Difficile Infection ◽

Post Infection ◽

Clinical Cure ◽

Oral Vancomycin ◽

End Of Treatment ◽

Severe Clostridium Difficile Infection ◽

The Impact ◽

Length Of Hospitalization

Abstract Background Treatment of severe Clostridium difficile infection (CDI) with oral vancomycin (oVAN) is known to be superior to treatment with metronidazole. However, previous studies have not evaluated the impact on patients when oVAN therapy is delayed after diagnosis or suspicion of severe CDI. Methods This was a single-center, retrospective study of adult patients who were diagnosed with severe CDI as defined by a white blood cell (WBC) count greater than 15,000 cells/mm3. The primary outcome was in-hospital mortality between patients treated initially with oVAN vs. delayed oVAN after metronidazole. Secondary outcomes included clinical cure by day 10, post-infection length of hospitalization, the time to resolution of leukocytosis and renal function at the end of treatment. Leukocytosis was defined as a WBC greater than 12,000 cells/mm3. Patients were excluded if they received oVAN for a previous episode of CDI, were receiving treatment for a concurrent infection, were receiving high-dose steroids, or received metronidazole or oVAN within 5 days preceding CDI diagnosis. Results A total of 121 patients were included. Overall, 49% of patients were female and the median age was 67 years old. 101 patients comprised the initial oVAN group, while 20 patients comprised the delayed oVAN group. Baseline demographics did not differ significantly between groups other than the time to initiation of oVAN (0.33 vs. 3.18 days, P < 0.001). There was no significant difference in in-hospital mortality for patients in the initial oVAN treatment group compared with those who had delayed oVAN therapy (5% vs. 15%, P = 0.13). Patients who received oVAN initially experienced a higher rate of clinical cure by day 10 (49.5% vs. 20%, P = 0.02), a shorter median post-infection length of hospitalization (7 days vs. 13 days, P < 0.001), a shorter median time to resolution of leukocytosis (3.9 days vs. 10.4 days, P = 0.01), and were less likely to have an end of treatment serum creatinine greater than 1.5 times their baseline (8.7% vs. 29.4%, P = 0.03). Conclusion Patients who receive oVAN as their initial treatment for severe CDI have improved clinical outcomes compared with those initially treated with metronidazole. Disclosures All authors: No reported disclosures.

Download Full-text